Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin in Arginine-vasopressin Deficiency
NCT04789148Phase 1Recruiting
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in arginine vasopressin deficiency (CDI) (8 arms). Primary endpoint: Anxious behavior assessed by Dot-probe task at 20 minutes. Started Sep 2025; status: recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
arginine vasopressin deficiency (CDI)
Beyond the preview
Go deeper on NCT04789148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789148.